On December 30, Tianjing Biotech and Jichuan Pharmaceutical jointly announced that based on a strategic judgment on the development trend of China's growth hormone market, in response to the country's new drug real estate policy, and based on the commercial advantages of real estate etane and the real estate promotion schedule that exceeded expectations, the two sides decided to fully implement the real estate strategy for etane recombinant human growth hormone injections.

On December 30, Tianjing Biotech and Jichuan Pharmaceutical jointly announced that based on a strategic judgment on the development trend of China's growth hormone market, in response to the country's new drug real estate policy, and based on the commercial advantages of real estate etane and the real estate promotion schedule that exceeded expectations, the two sides decided to fully implement the real estate strategy for etane recombinant human growth hormone injections.